Long-term primary human tumor cell cultures and mixed autologous tumor-lymphocyte cultures for adoptive specific antitumoral immunotherapy.

Abstract

Anticancer immunotherapy may improve the body's cancer defences, quality of life and survival. Encouraging treatment models have been proposed, namely the non-specific LAK and ALT cell therapies; the relatively specific TIL/CTL cell therapy as well as allogenic cancer vaccines; autologous cancer vaccines. A procedure to prepare an autologous antitumor serum for cancer therapy using ex vivo activated autologous cells is here reported. Peripheral blood lymphocytes obtained by leukaphoresis were cultured with autologous tumor cells in RPM1 1640 and rh-IL-2 for 48 hours at 37 degrees C in a humidified, CO2 enriched atmosphere. The cytokine rich supernatant, as well as the activated cells in medium were frozen, lysed and aliquotted, frozen, and stored at -20 degrees C. The material was used for specific anticancer immunotherapy. Fibroblast-free tumor cells are being maintained in long term culture for future ex vivo sensitization of autologous cells.

Cite this paper

@article{Rizzo1998LongtermPH, title={Long-term primary human tumor cell cultures and mixed autologous tumor-lymphocyte cultures for adoptive specific antitumoral immunotherapy.}, author={Sebastiano Rizzo and Maria Grazia Silvotti and F Martano and Annette B Santamaria and Paulo Pontiggia}, journal={Anticancer research}, year={1998}, volume={18 1A}, pages={41-4} }